SecBot SecBot
SECBOTREPLAY Home › Report › SYRE

SYRE · Four insiders at Spyre Therapeutics, including the CEO, CFO, and CMO,…

Spyre Therapeutics, Inc. · CLUSTER filed Apr 30, 2026 at 20:00 ET

At the news

NEUTRALIMPACT 3/10

CLUSTER filed Apr 30, 2026 at 20:00 ET

Four insiders at Spyre Therapeutics, including the CEO, CFO, and CMO, sold a total of $2.92M in open-market sales over a 7-day window ending May 8, 2026. The sales follow a Q1 earnings report showing a wider net loss of $69.0M, though the company highlighted positive Phase 2 data and a strong cash runway. The cluster value represents ~0.05% of the $6.3B market cap, which is trivial and routine for a biotech of this size.

  • Four insiders sold shares totaling $2.92M in open-market transactions from May 1-8, 2026.
  • CEO Turtle Cameron sold $369K, CFO Scott Burrows sold $892K, CMO Sheldon Sloan sold $1.48M, and Director Michael Henderson sold $174K.
  • Total cluster value is ~0.05% of SYRE's $6.3B market cap, well below the 0.1% materiality threshold.
  • Sales occurred 4 days after Q1 2026 earnings reported a net loss of $69.0M, wider than the $44.8M loss in Q1 2025.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access